Heart Failure: 68-Market Analysis and Sales Forecast

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Heart Failure (HF) market through 2032.

Across the 68 markets, sales in the heart failure market were $21.6 billion in 2022, growing to $65.7 billion in 2032.

The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 62.5% and 51.4% of 68-market sales in 2022 and 2032, respectively.

Scope

• This publication is an expanded version of the Excel model containing the patient-based forecast sales for heart failure (HF), covered in GlobalData's report "Heart Failure: Seven -Market Drug Forecast and Market Analysis Update", published in November 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM HF therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HF therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.